The open-label, single-center, dose-escalation trial began enrollment in May 2022 and concluded in March 2024 ... positioning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback